{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:12:13Z","timestamp":1784344333015,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T00:00:00Z","timestamp":1479859200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Pfizer Hellas"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40256-016-0204-1","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T17:18:36Z","timestamp":1479921516000},"page":"123-133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective"],"prefix":"10.1007","volume":"17","author":[{"given":"Kostas","family":"Athanasakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Boubouchairopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftheria","family":"Karampli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippos","family":"Tarantilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Savvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Bilitou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kyriopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,23]]},"reference":[{"key":"204_CR1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/hrt.2003.014720","volume":"90","author":"JS Steinberg","year":"2004","unstructured":"Steinberg JS. Atrial fibrillation: an emerging epidemic? Heart. 2004;90:239\u201340.","journal-title":"Heart"},{"key":"204_CR2","unstructured":"National Institute for Health and Clinical Excellence. Guideline 180-Atrial fibrillation: the management of atrial fibrillation. https:\/\/www.nice.org.uk\/guidance\/cg180\/resources\/guidance-atrial-fibrillation-the-management-of-atrial-fibrillation-pdf . Accessed Sept 2015."},{"key":"204_CR3","first-page":"173","volume":"2013","author":"RA Kaba","year":"2013","unstructured":"Kaba RA, Camm AJ, Williams TM, Sharma R. Managing atrial fibrillation in the global community: the European perspective. Glob Cardiol Sci Pract. 2013;2013:173\u2013184","journal-title":"Glob Cardiol Sci Pract"},{"key":"204_CR4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.amjcard.2015.05.045","volume":"116","author":"MP Turakhia","year":"2015","unstructured":"Turakhia MP, Shafrin J, Bognar K, Goldman DP, Mendys PM, Abdulsattar Y, et al. Economic burden of undiagnosed nonvalvular atrial fibrillation in the United States. Am J Cardiol. 2015;116:733\u20139.","journal-title":"Am J Cardiol"},{"key":"204_CR5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.mcna.2015.02.007","volume":"99","author":"T Moukabary","year":"2015","unstructured":"Moukabary T, Gonzalez MD. Management of atrial fibrillation. Med Clin North Am. 2015;99:781\u201394.","journal-title":"Med Clin North Am"},{"key":"204_CR6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","volume":"114","author":"Y Miyasaka","year":"2006","unstructured":"Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119\u201325.","journal-title":"Circulation"},{"key":"204_CR7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837\u201347.","journal-title":"Circulation"},{"key":"204_CR8","first-page":"48","volume":"53","author":"P Korantzopoulos","year":"2012","unstructured":"Korantzopoulos P, Andrikopoulos G, Vemmos K, Goudevenos JA, Vardas PE. Atrial fibrillation and thromboembolic risk in Greece. Hellenic J Cardiol. 2012;53:48\u201354.","journal-title":"Hellenic J Cardiol"},{"key":"204_CR9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/AC.67.1.2146567","volume":"67","author":"G Ntaios","year":"2012","unstructured":"Ntaios G, Manios E, Synetou M, Savvari P, Vemmou A, et al. Prevalence of atrial fibrillation in Greece: the arcadia rural study on atrial fibrillation. Acta Cardiol. 2012;67:65\u20139.","journal-title":"Acta Cardiol"},{"key":"204_CR10","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983\u20138.","journal-title":"Stroke"},{"key":"204_CR11","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","volume":"14","author":"AJ Camm","year":"2012","unstructured":"Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation\u2013developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385\u2013413.","journal-title":"Europace."},{"key":"204_CR12","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.STR.0000166053.83476.4a","volume":"36","author":"C Marini","year":"2005","unstructured":"Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36:1115\u20139.","journal-title":"Stroke"},{"key":"204_CR13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.STR.32.2.392","volume":"32","author":"M Lamassa","year":"2001","unstructured":"Lamassa M, Di Carlo A, Pracucci G, Basile AM, Trefoloni G, Vanni P, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke. 2001;32:392\u20138.","journal-title":"Stroke"},{"key":"204_CR14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/01.ede.0000091649.26364.c0","volume":"14","author":"J Friberg","year":"2003","unstructured":"Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology. 2003;14:666\u201372.","journal-title":"Epidemiology."},{"key":"204_CR15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clineuro.2015.12.013","volume":"142","author":"P Kritikou","year":"2016","unstructured":"Kritikou P, Spengos K, Zakopoulos N, Tountas Y, Yfantopoulos J, Vemmos K. Resource utilization and costs for treatment of stroke patients in an acute stroke unit in Greece. Clin Neurol Neurosurg. 2016;142:8\u201314.","journal-title":"Clin Neurol Neurosurg"},{"key":"204_CR16","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.STR.27.10.1765","volume":"27","author":"HS J\u00f8rgensen","year":"1996","unstructured":"J\u00f8rgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke. 1996;27:1765\u20139.","journal-title":"The Copenhagen Stroke Study. Stroke."},{"key":"204_CR17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/europace\/eun048","volume":"10","author":"A Ringborg","year":"2008","unstructured":"Ringborg A, Nieuwlaat R, Lindgren P, J\u00f6nsson B, Fidan D, Maggioni AP, et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace. 2008;10:403\u201311.","journal-title":"Europace."},{"key":"204_CR18","doi-asserted-by":"crossref","unstructured":"European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360\u2013420.","DOI":"10.1093\/europace\/euq350"},{"key":"204_CR19","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jacc.2010.09.013","volume":"57","author":"V Fuster","year":"2011","unstructured":"Fuster V, Ryd\u00e9n LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF\/AHA\/HRS focused updates incorporated into the ACC\/AHA\/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57:e101\u201398.","journal-title":"J Am Coll Cardiol"},{"key":"204_CR20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000131083","volume":"25","author":"European Stroke Organisation","year":"2008","unstructured":"European Stroke Organisation. (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457\u2013507.","journal-title":"Cerebrovasc Dis."},{"key":"204_CR21","unstructured":"Kirschhof P, Adamou A, Knight E, Lip GYH, Norrving B, de Pouvourville G, et al. Working Group Report: Stroke Prevention in Patients with Atrial Fibrillation. 2009. http:\/\/ec.europa.eu\/health-eu\/doc\/strokecrisis.pdf . Accessed Sept 2015."},{"key":"204_CR22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11239-011-0561-1","volume":"31","author":"E Nutescu","year":"2011","unstructured":"Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31:326\u201343.","journal-title":"J Thromb Thrombolysis"},{"key":"204_CR23","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1053\/euhj.2000.2300","volume":"22","author":"V Frykman","year":"2001","unstructured":"Frykman V, Beerman B, Ryd\u00e9n L, Rosenqvist M, Medical Products Agency; Swedish Society of Cardiology. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J. 2001;22:1954\u20139.","journal-title":"Eur Heart J"},{"key":"204_CR24","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857\u201367.","journal-title":"Ann Intern Med"},{"issue":"35","key":"204_CR25","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.2174\/1381612821666150915110322","volume":"21","author":"R Casado-Arroyo","year":"2015","unstructured":"Casado-Arroyo R, Lanas A, Brugada P. A balanced view of efficacy and safety of aspirin in cardiovascular diseases. Curr Pharm Des. 2015;21(35):5101\u20137.","journal-title":"Curr Pharm Des"},{"key":"204_CR26","unstructured":"European Medicines Agency. Summary of opinion (post authorisation)\u2014Eliquis (apixaban). EMA. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/002148\/WC500132869.pdf . Accessed Sept 2015."},{"key":"204_CR27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"204_CR28","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806\u201317.","journal-title":"N Engl J Med"},{"key":"204_CR29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/europace\/euv304","volume":"18","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network\/European Heart Rhythm Association consensus conference. Europace. 2016;18:37\u201350.","journal-title":"Europace."},{"key":"204_CR30","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/eurheartj\/ehu006","volume":"35","author":"P Dorian","year":"2014","unstructured":"Dorian P, Kongnakorn T, Phatak H, Rublee DA, Kuznik A, Lanitis T, et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J. 2014;35:1897\u2013906.","journal-title":"Eur Heart J"},{"key":"204_CR31","unstructured":"Greek Ministry of Health. Official pricelists, Athens. http:\/\/www.moh.gov.gr\/articles\/times-farmakwn\/deltia-timwn . Accessed 15 Jan 2016."},{"key":"204_CR32","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","volume":"380","author":"RD Lopes","year":"2012","unstructured":"Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012;380:1749\u201358.","journal-title":"Lancet"},{"key":"204_CR33","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1161\/STROKEAHA.114.005746","volume":"45","author":"GY Lip","year":"2014","unstructured":"Lip GY, Eikelboom J, Yusuf S, Shestakovska O, Hart RG, Connolly S, et al. Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Stroke. 2014;45:2127\u201330.","journal-title":"Stroke"},{"key":"204_CR34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCEP.112.975847","volume":"6","author":"GY Lip","year":"2013","unstructured":"Lip GY, Connolly S, Yusuf S, Shestakovska O, Flaker G, Hart R, et al. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Circ Arrhythm Electrophysiol. 2013;6:31\u20138.","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"204_CR35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1600-0404.2008.01014.x","volume":"118","author":"G Gioldasis","year":"2008","unstructured":"Gioldasis G, Talelli P, Chroni E, Daouli J, Papapetropoulos T, Ellul J. In-hospital direct cost of acute ischemic and hemorrhagic stroke in Greece. Acta Neurol Scand. 2008;118:268\u201374.","journal-title":"Acta Neurol Scand"},{"key":"204_CR36","first-page":"250","volume":"8","author":"M Geitona","year":"1999","unstructured":"Geitona M, Papadimitriou A, Kyriopoulos J. Economic Evaluation of prevention of cerebral strokes via the administration of dipyridamol and aspirin twice daily. Neurologia. 1999;8:250\u20137.","journal-title":"Neurologia."},{"key":"204_CR37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0272989X11401031","volume":"31","author":"P Sullivan","year":"2011","unstructured":"Sullivan P, Slejko J, Sculpher M, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31:800\u20134.","journal-title":"Med Decis Making"},{"key":"204_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","volume":"154","author":"JV Freeman","year":"2011","unstructured":"Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1\u201311.","journal-title":"Ann Intern Med"},{"key":"204_CR39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","volume":"7","author":"HG Eichler","year":"2004","unstructured":"Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518\u201328.","journal-title":"Value Health"},{"key":"204_CR40","unstructured":"World Health Organization. Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. In: WHO Commission on Macroeconomics and Health: Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva: WHO; 2001."},{"key":"204_CR41","doi-asserted-by":"crossref","first-page":"e103974","DOI":"10.1371\/journal.pone.0103974","volume":"9","author":"J Stevanovi\u0107","year":"2014","unstructured":"Stevanovi\u0107 J, Pompen M, Le HH, Rozenbaum MH, Tieleman RG, Postma MJ. Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. PLoS One. 2014;9:e103974.","journal-title":"PLoS One"},{"key":"204_CR42","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3111\/13696998.2014.923891","volume":"17","author":"T Lanitis","year":"2014","unstructured":"Lanitis T, Cott\u00e9 FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. J Med Econ. 2014;17:587\u201398.","journal-title":"J Med Econ."},{"key":"204_CR43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40261-014-0224-z","volume":"34","author":"T Kongnakorn","year":"2014","unstructured":"Kongnakorn T, Lanitis T, Lieven A, Thijs V, Marbaix S. Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. Clin Drug Investig. 2014;34:709\u201321.","journal-title":"Clin Drug Investig"},{"key":"204_CR44","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/2047487313514019","volume":"22","author":"Z Ademi","year":"2015","unstructured":"Ademi Z, Pasupathi K, Liew D. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia. Eur J Prev Cardiol. 2015;22:344\u201353.","journal-title":"Eur J Prev Cardiol."},{"key":"204_CR45","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/CIRCOUTCOMES.112.965251","volume":"5","author":"S Lee","year":"2012","unstructured":"Lee S, Anglade MW, Meng J, Hagstrom K, Kluger J, Coleman CI. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Circ Cardiovasc Qual Outcomes. 2012;5:472\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"204_CR46","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.thromres.2014.05.027","volume":"134","author":"T Lanitis","year":"2014","unstructured":"Lanitis T, Kongnakorn T, Jacobson L, De Geer A. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. Thromb Res. 2014;134:278\u201387.","journal-title":"Thromb Res"},{"key":"204_CR47","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCOUTCOMES.113.000661","volume":"6","author":"WJ Canestaro","year":"2013","unstructured":"Canestaro WJ, Patrick AR, Avorn J, Ito K, Matlin OS, Brennan TA, et al. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2013;6:724\u201331.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"204_CR48","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/STROKEAHA.111.000402","volume":"44","author":"AR Harrington","year":"2013","unstructured":"Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44:1676\u201381.","journal-title":"Stroke"},{"key":"204_CR49","doi-asserted-by":"crossref","first-page":"e47473","DOI":"10.1371\/journal.pone.0047473","volume":"7","author":"S Lee","year":"2012","unstructured":"Lee S, Mullin R, Blazawski J, Coleman CI. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One. 2012;7:e47473.","journal-title":"PLoS One"},{"key":"204_CR50","doi-asserted-by":"crossref","first-page":"e62183","DOI":"10.1371\/journal.pone.0062183","volume":"8","author":"BL Limone","year":"2013","unstructured":"Limone BL, Baker WL, Kluger J, Coleman CI. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One. 2013;8:e62183.","journal-title":"PLoS One"},{"key":"204_CR51","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1136\/hrt.2005.072173","volume":"92","author":"R Luengo-Fernandez","year":"2006","unstructured":"Luengo-Fernandez R, Leal J, Gray A, Petersen S, Rayner M. Cost of cardiovascular diseases in the United Kingdom. Heart. 2006;92:1384\u20139.","journal-title":"Heart"},{"key":"204_CR52","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/heart.88.6.597","volume":"88","author":"JL Liu","year":"2002","unstructured":"Liu JL, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart. 2002;88:597\u2013603.","journal-title":"Heart"},{"key":"204_CR53","unstructured":"European Medicine Agency. Eliquis summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf . Accessed 10 Dec 2015."},{"key":"204_CR54","unstructured":"Beswick AD, Rees K, Griebsch I, et al. Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups. Health Technol Assess. 2004;8(41):iii\u2013iv, ix\u2013x, 1\u2013152."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0204-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-016-0204-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0204-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T22:22:13Z","timestamp":1568586133000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-016-0204-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,23]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["204"],"URL":"https:\/\/doi.org\/10.1007\/s40256-016-0204-1","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,23]]}}}